Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
Titel:
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
Auteur:
van Kampen, R.J.W. Ramaekers, B.L.T. Lobbezoo, D.J.A. de Boer, M. Dercksen, M.W. van den Berkmortel, F. Smilde, T.J. van de Wouw, A.J. Peters, F.P.J. van Riel, J.M.G. Peters, N.A.J.B. Tjan-Heijnen, V.C.G. Joore, M.A.